FDA's Real World Study On Adoption Of PD-1 Dosing Change Aims To Inform Reviewers
Executive Summary
Study using US FDA’s Information Exchange and Data Transformation (INFORMED) program will focus on shift from weight-based to flat dosing for Opdivo and Keytruda.
You may also be interested in...
Real-World Evidence Takes Courage: A Conversation With IQVIA’s Nancy Dreyer
Emerging standards for regulatory use of RWE should resist the temptation to impose the standards and expectations of randomized clinical trials to a fundamentally different kind of evidence, Dreyer cautions.
Real-World Evidence: US FDA Framework Emphasizes Data Fitness And Study Quality
Agency’s approach to assessing real-world evidence for effectiveness will be guided by three key principles: fitness for use of the underlying data, adequacy of the study design, and satisfactory monitoring and data collection.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.